Back to search
FDAFDA · Food and drugs·Recall number D-1351-2022

Fulvestrant Injection 250mg/5mL (50 mg/mL), Contains 2 Single-Dose Prefilled Syringes, Rx Only, Product of India, Manufactured by: Cadila Healthcare Limited, Ahmadabad, India, Distributed by: Zydus Pharmaceuticals (USA ) Inc.m Pennington, NJ 08534, NDC 70710-1688-8.

Published August 24, 2022 · Recall initiated: July 15, 2022

Summary

FDA records drug Class II recall D-1351-2022, published August 24, 2022 and initiated July 15, 2022. Recalling firm: Zydus Pharmaceuticals (USA) Inc; Status: Terminated; Reported quantity: 1116 boxes; Lot: Lot # B200076; Exp 31 JAN 2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email if FULVESTRANT has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
FULVESTRANT
Manufacturer
Zydus Pharmaceuticals (USA) Inc
Distributor
Nationwide.
Lot
Lot # B200076; Exp 31 JAN 2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Fulvestrant Injection 250mg/5mL (50 mg/mL), Contains 2 Single-Dose Prefilled Syringes, Rx Only, Product of India, Manufactured by: Cadila Healthcare Limited, Ahmadabad, India, Distributed by: Zydus Pharmaceuticals (USA ) Inc.m Pennington, NJ 08534, NDC 70710-1688-8. recalled?

Yes. FDA published recall D-1351-2022 on August 24, 2022. Reported hazard: Failed Impurities/Degradation Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: FULVESTRANT.